We are live on !
Find out more
Cliff Asness AQR Capital Management
AUM
$287B
Turnover
8.35%
1-Year Est. Return
42.33%
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
This Fund
S&P 500
This Quarter Est. Return
+22.95%
1 Year Est. Return
+42.33%
3 Year Est. Return
+119.89%
5 Year Est. Return
+147.33%
10 Year Est. Return
+543.74%
AUM
$287B
AUM Growth
+$68.5B
(+31%)
Cap. Flow
+$37.5B
Cap. Flow % of AUM
Cap. Flow %
13.08%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
3,986
New
247
Increased
2,455
Reduced
1,098
Closed
86
Avg Time Held
4.1
years
Top 10 Avg Time Held
3.3
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.17B |
| 2 |
Apple
AAPL
|
+$849M |
| 3 |
Chevron
CVX
|
+$746M |
| 4 |
Synopsys
SNPS
|
+$643M |
| 5 |
Wells Fargo
WFC
|
+$633M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$517M |
| 2 |
Booking.com
BKNG
|
+$488M |
| 3 |
Walmart Inc
WMT
|
+$414M |
| 4 |
Sandisk
SNDK
|
+$355M |
| 5 |
Cigna
CI
|
+$325M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.5% |
| 2 | Financials | 14.38% |
| 3 | Industrials | 14.2% |
| 4 | Consumer Discretionary | 10.53% |
| 5 | Healthcare | 10.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2751
CF Bankshares
CFBK
$231M
| $1.61M | ﹤0.01% |
49,122
+10,474
| +27% | +$304K |
2025 Q3
3 quarters
|
|
2752
Invesco S&P 500 Top 50 ETF
XLG
$11.6B
| $1.61M | ﹤0.01% |
26,274
-5,113
| -16% | -$312K |
2025 Q2
4 quarters
|
|
2753
First Trust Value Line Dividend Fund
FVD
$8.09B
| $1.61M | ﹤0.01% |
33,378
-949
| -3% | -$45.2K |
2024 Q3
7 quarters
|
|
2754
Protagonist Therapeutics
PTGX
$9.37B
| $1.61M | ﹤0.01% |
13,096
+1,222
| +10% | +$128K |
2023 Q2
12 quarters
|
|
2755
NCR Voyix
VYX
$1.17B
| $1.61M | ﹤0.01% |
201,035
+59,719
| +42% | +$420K |
2019 Q4
26 quarters
|
|
2756
Central Garden & Pet Co
CENT
$2.85B
| $1.6M | ﹤0.01% |
36,127
+10,186
| +39% | +$399K |
2025 Q1
5 quarters
|
|
2757
Information Services Group
III
$295M
| $1.6M | ﹤0.01% |
388,980
+85,384
| +28% | +$357K |
2024 Q2
8 quarters
|
|
2758
Hawkins
HWKN
$3.17B
| $1.6M | ﹤0.01% |
11,248
+1,034
| +10% | +$163K |
2020 Q3
23 quarters
|
|
2759
Capital Group U.S. Small and Mid Cap ETF
CGMM
$3.49B
| $1.6M | ﹤0.01% |
48,470
+27,863
| +135% | +$877K |
2025 Q3
3 quarters
|
|
2760
Rezolve AI
RZLV
$609M
| $1.59M | ﹤0.01% |
505,281
-381,779
| -43% | -$1M |
2025 Q4
2 quarters
|
|
2761
Invesco KBW Bank ETF
KBWB
$6.28B
| $1.59M | ﹤0.01% |
17,115
+11,235
| +191% | +$983K |
2025 Q2
4 quarters
|
|
2762
Goldman Sachs Physical Gold ETF Shares
AAAU
$2.36B
| $1.59M | ﹤0.01% |
40,098
+33,848
| +542% | +$1.51M |
2026 Q1
1 quarter
|
|
2763
WisdomTree Dynamic International Equity Fund
DDWM
$1.42B
| $1.58M | ﹤0.01% |
34,293
| – | – |
2026 Q1
1 quarter
|
|
2764
Enerflex
EFXT
$2.89B
| $1.58M | ﹤0.01% |
64,399
+8,944
| +16% | +$223K |
2025 Q4
2 quarters
|
|
2765
One Liberty Properties
OLP
$489M
| $1.58M | ﹤0.01% |
64,562
+17,970
| +39% | +$420K |
2025 Q4
2 quarters
|
|
2766
Nektar Therapeutics
NKTR
$1.33B
| $1.57M | ﹤0.01% |
+22,542
| New | +$1.65M |
2026 Q2
0 quarters
|
|
2767
Electromed
ELMD
$224M
| $1.57M | ﹤0.01% |
37,141
+22,471
| +153% | +$720K |
2026 Q1
1 quarter
|
|
2768
JPMorgan Diversified Return US Equity ETF
JPUS
$467M
| $1.57M | ﹤0.01% |
11,193
| – | – |
2024 Q1
9 quarters
|
|
2769
Metallus
MTUS
$875M
| $1.57M | ﹤0.01% |
83,941
+26,268
| +46% | +$493K |
2020 Q2
24 quarters
|
|
2770
GigaCloud Technology
GCT
$2.08B
| $1.57M | ﹤0.01% |
49,579
-7,116
| -13% | -$281K |
2024 Q3
7 quarters
|
|
2771
VictoryShares Free Cash Flow ETF
VFLO
$12.2B
| $1.56M | ﹤0.01% |
34,107
-3,647
| -10% | -$159K |
2025 Q1
5 quarters
|
|
2772
CRISPR Therapeutics
CRSP
$4.97B
| $1.56M | ﹤0.01% |
28,597
+6,329
| +28% | +$334K |
2025 Q1
5 quarters
|
|
2773
aTyr Pharma
ATYR
$12.4M
| $1.56M | ﹤0.01% |
65,264
+52,864
| +426% | +$1.38M |
2025 Q4
2 quarters
|
|
2774
Aktis Oncology
AKTS
$886M
| $1.55M | ﹤0.01% |
+48,123
| New | +$988K |
2026 Q2
0 quarters
|
|
2775
Recursion Pharmaceuticals
RXRX
$2.41B
| $1.55M | ﹤0.01% |
422,087
+177,696
| +73% | +$592K |
2026 Q1
1 quarter
|
|
Similar funds
Cliff Asness's Q2 2026 Portfolio in Review
As of Q2 2026, Cliff Asness held 3,986 positions worth $287B, up 31% from $218B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Cliff Asness deployed $37.5B of net new capital in Q2 2026, opening 247 new positions and adding to 2,455 existing holdings. Its largest new stake was FedEx Freight: 1,024,555 shares worth $155M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 22% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Micron Technology, an estimated $517M trimmed.
- Cliff Asness's largest Q2 2026 buy was FedEx Freight: 1,024,555 shares worth $155M.
- Cliff Asness added most to NVIDIA in Q2 2026, an estimated $1.17B increase.
- Cliff Asness's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $517M.
- Cliff Asness fully exited Masimo in Q2 2026, selling an estimated $147M.
- Cliff Asness's ten largest holdings make up 12% of its $287B portfolio in Q2 2026.
- Cliff Asness opened 247 new positions and closed 86 in Q2 2026.
- Cliff Asness's portfolio value rose 31% quarter-over-quarter to $287B.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.